Low-Intensity Fludarabine, Cyclophosphamyde, Rituximab (FCR) as Front-Line Treatment for Follicular Lymphoma. Efficacy and Toxicity Profile of the Oral Versus Intravenous Administration

被引：0
|
作者：
Marin-Niebla, Ana [1 ]
Rios-Herranz, Eduardo [2 ]
de la Cruz Vicente, Faatima, Jr. [1 ]
Cerezuela, Paula [1 ]
Falantes, Jose Francisco [1 ]
Martino, Mariluz [1 ]
Espigado, Ildefonso [3 ]
Ispizua, Alvaro Urbano [1 ]
机构：
[1] Hosp Univ Virgen del Rocio, Hematol & Hemotherapy Dept, Seville, Spain
[2] Hosp Univ Virgen de Valme, Dept Hematol, Seville, Spain
[3] BM Failure Spanish Study Grp Pethema GETH, Seville, Spain
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1052 / 1053
页数：2
相关论文
共 11 条
  • [1] EFFICACY AND SAFETY OF LOW-INTENSITY ORAL AND INTRAVENOUS FLUDARABINE-CYCLOPHOSPHAMYDE WITH AND WITHOUT RITUXIMAB FOR FIRST-LINE TREATMENT OF FOLLICULAR LYMPHOMA
    Marin-Niebla, A.
    Rios-Herranz, E.
    Falantes Gonzalez, J. E.
    Cerezuela, P.
    Martino Galiana, M. L.
    Parody Ruiz-Berdejo, R.
    Urbano-Ispizua, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 397 - 397
  • [2] Rituximab and Chlorambucil as Front-Line Treatment in Untreated Follicular Lymphoma: a Combination with a Durable Response and Low Toxicity Profile
    Bassi, Simona
    Nassi, Luca
    Pruneri, Giancarlo
    Sammassimo, Simona
    Bertazzoni, Paola
    Gigli, Federica
    Vanazzi, Anna
    Cocorocchio, Emilia
    Mancuso, Patrizia
    Rabascio, Cristina
    Lionetti, Maria Teresa
    Laszlo, Daniele
    Martinelli, Giovanni
    BLOOD, 2009, 114 (22) : 1445 - 1445
  • [3] Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma
    Zinzani, PL
    Pulsoni, A
    Perrotti, A
    Soverini, S
    Zaja, F
    De Renzo, A
    Storti, S
    Lauta, VM
    Guardigni, L
    Gentilini, P
    Tucci, A
    Molinari, AL
    Gobbi, M
    Falini, B
    Fattori, PP
    Ciccone, F
    Alinari, L
    Martelli, M
    Pileri, S
    Tura, S
    Baccarani, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) : 2654 - 2661
  • [4] Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study
    Herishanu, Yair
    Levi, Shai
    Goldschmidt, Neta
    Morabito, Fortunato
    Bairey, Osnat
    Del Poeta, Giovanni
    Baran, Tomer Ziv
    Fineman, Riva
    Mauro, Francesca Romana
    Gutwein, Odit
    Reda, Gianluigi
    Ruchlemer, Rosa
    Sportoletti, Paolo
    Laurenti, Luca
    Shvidel, Lev
    Coscia, Marta
    Tadmor, Tamar
    Varettoni, Marzia
    Aviv, Ariel
    Murru, Roberta
    Breaster, Andrei
    Bronstein, Yotam
    Chiarenza, Annalisa
    Visentin, Andrea
    Pietrasanta, Daniela
    Loseto, Giacomo
    Zucchetto, Antonella
    Bomben, Riccardo
    Olivieri, Jacopo
    Neri, Antonino
    Rossi, Davide
    Gaidano, Gianluca
    Trentin, Livio
    Foa, Robin
    Cuneo, Antonio
    Gattei, Valter
    Gentile, Massimo
    BLOOD, 2021, 138
  • [5] RITUXIMAB AND CHLORAMBUCIL AS FRONT-LINE TREATMENT FOR FOLLICULAR LYMPHOMA: EXTENDED DISEASE FREE SURVIVAL WITHOUT INCREASED TOXICITY
    Bassi, S.
    Sammassimo, S.
    Gigli, F.
    Negri, M.
    Cocorocchio, E.
    Gardellini, A.
    Rabascio, C.
    Calleri, A.
    Pruneri, G.
    Peccatori, F.
    Laszlo, D.
    Martinelli, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 109 - 109
  • [6] EFFICACY AND TOXICITY OF IMMUNO CHEMOTHERAPY AND MAINTENANCE WITH RITUXIMAB IN THE FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA. EXPERIENCE OF A CENTRE
    Barranco Pilar, Martinez
    Francisco Javier, Penalver Parraga
    Blanco Lucia, Villalon
    Juaristi Karmele, Arribalzaga
    Maria Jose, Garcia Bueno
    Andres Pilar, Ricard
    HAEMATOLOGICA, 2016, 101 : 365 - 366
  • [7] A randomized trial of fludarabine and mitoxantrone plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma.
    Zinzani, PL
    BLOOD, 2001, 98 (11) : 842A - 842A
  • [8] Safety and Efficacy of Combination Therapy with Fludarabine, Mitoxantrone, and Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan and Maintenance Rituximab as Front-Line Therapy for Patients With Follicular or Marginal Zone Lymphoma
    Karmali, Reem
    Kassar, Mohamad
    Venugopal, Parameswaran
    Shammo, Jamile M.
    Fung, Henry C.
    Bayer, Robert
    O'Brien, Teresa
    Gregory, Stephanie A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (06): : 467 - 474
  • [9] FCR (Fludarabine, Cyclophosphamide, Rituximab) Followed By 90yttrium Ibritumomab Tiuxetan for the Treatment of Relapsed Grades 1 and 2 Follicular Lymphoma. Long Term Efficacy and Safety Results of 9 Cases
    Pisani, Francesco
    Dessanti, Maria Laura
    Giannarelli, Diana
    Kayal, Ramy
    Marchesi, Francesco
    Sciuto, Rosa
    Rea, Sandra
    Maini, Carlo Ludovico
    Marino, Mirella
    BLOOD, 2014, 124 (21)
  • [10] Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
    Davies, Andrew
    Merli, Francesco
    Mihaljevic, Biljana
    Mercadal, Santiago
    Siritanaratkul, Noppadol
    Solal-Celigny, Philippe
    Boehnke, Axel
    Berge, Claude
    Genevray, Magali
    Zharkov, Artem
    Dixon, Mark
    Brewster, Michael
    Barrett, Martin
    MacDonald, David
    LANCET HAEMATOLOGY, 2017, 4 (06): : E272 - E282
12